Carboplatin AUC Dosing Calculator

About the Carboplatin AUC Dosing Calculator

The Carboplatin AUC Dosing Calculator uses the Calvert formula to calculate individualized carboplatin doses based on renal function and a target area under the concentration-time curve (AUC). Unlike most chemotherapy agents dosed by body surface area (BSA), carboplatin's pharmacokinetics are dominated by renal clearance, making GFR-based dosing essential for consistent drug exposure across patients.

The Calvert formula, published in 1989 by Calvert et al. in the Journal of Clinical Oncology, revolutionized platinum-based chemotherapy by demonstrating that dose = target AUC × (GFR + 25), where GFR is glomerular filtration rate in mL/min and 25 represents a constant for non-renal clearance. This approach reduces the wide inter-patient variability in carboplatin exposure that occurs with BSA-based dosing, leading to more predictable efficacy and toxicity.

This calculator accepts either directly measured GFR (from nuclear medicine studies like Tc-99m DTPA or iohexol clearance) or estimates creatinine clearance using the Cockcroft-Gault equation. It applies the FDA-recommended GFR cap of 125 mL/min (modifiable) to prevent inadvertent overdosing in patients with high renal function — a safety measure introduced after reports of severe toxicity with uncapped dosing. The tool also provides AUC range references for common cancer indications and important safety reminders for clinical practice.

When This Page Helps

Carboplatin dosing errors can cause life-threatening toxicity or treatment failure. The Calvert formula is standard of care, but manual calculations introduce human error, especially when GFR capping, Cockcroft-Gault estimation, and ideal body weight adjustments are needed. This calculator automates the process with built-in safety checks and clinical reference data.

How to Use the Inputs

1. Enter the target AUC prescribed by the oncologist (typically 4–7 mg·min/mL depending on indication).
2. Select whether to use a measured GFR or estimate CrCl via the Cockcroft-Gault equation.
3. If using Cockcroft-Gault, enter serum creatinine, age, weight, and sex.
4. Optionally enter height for BSA calculation and dose-per-m² comparison.
5. Review the FDA GFR cap (default 125 mL/min) and adjust if institutional protocol differs.
6. Check the calculated dose, noting whether GFR capping was applied.
7. Refer to the AUC targets table to verify the prescribed AUC is appropriate for the indication.
8. Verify the dose with an oncology pharmacist before administration.

Example Calculation

Tips & Best Practices

• Always verify carboplatin doses with an oncology pharmacist — chemotherapy dosing errors can be fatal.
• Use measured GFR (nuclear scan) when available for the most accurate dosing.
• For obese patients, consider using ideal or adjusted body weight in the Cockcroft-Gault equation.
• Round the final dose per institutional protocol (commonly to the nearest 5 or 10 mg).
• Recheck renal function before each cycle and recalculate the dose if GFR has changed.
• The "25" constant in the Calvert formula represents non-renal clearance and is not adjusted for most patients.

History of AUC-Based Dosing

Before the Calvert formula, carboplatin was dosed like cisplatin — by BSA (mg/m²). This caused wide variability in toxicity: patients with poor renal function received toxic exposures, while those with excellent kidney function were potentially undertreated. Calvert's 1989 landmark paper demonstrated that targeting AUC produced more predictable outcomes, and this approach has been standard practice for over three decades.

GFR Measurement Methods

The gold standard for GFR is measured by nuclear medicine techniques (Tc-99m DTPA, Cr-51 EDTA) or iohexol clearance. When measured GFR is unavailable, the Cockcroft-Gault equation provides a reasonable estimate. Importantly, laboratories now routinely report CKD-EPI eGFR, which is NOT validated for Calvert formula use and can lead to dosing discrepancies of 10–20%.

Special Populations

In elderly patients, GFR naturally declines, and the Calvert formula appropriately reduces the carboplatin dose. In obese patients, Cockcroft-Gault using actual body weight overestimates CrCl; many institutions use adjusted body weight (ideal + 0.4 × excess). In patients with ascites or significant fluid shifts, renal function and drug distribution may be altered, requiring clinical judgment beyond formula-based dosing.

Frequently Asked Questions

• What is AUC in carboplatin dosing?

  AUC stands for Area Under the plasma concentration-time Curve, measured in mg·min/mL. It represents total drug exposure over time. Targeting a specific AUC ensures consistent carboplatin exposure regardless of individual renal function.

• Why is carboplatin dosed by AUC instead of BSA?

  Carboplatin is primarily eliminated by the kidneys, and renal function varies widely between patients. BSA-based dosing leads to 2–3 fold variability in drug exposure. AUC-based dosing via the Calvert formula normalizes exposure, improving the balance between efficacy and toxicity.

• What is the FDA GFR cap and why does it matter?

  The FDA recommends capping the GFR at 125 mL/min when calculating carboplatin doses to prevent overdosing in patients with high renal function. Without the cap, patients with GFR > 125 would receive doses that exceed safe exposure limits, increasing the risk of severe myelosuppression.

• Should I use Cockcroft-Gault or CKD-EPI for carboplatin dosing?

  The Calvert formula was developed and validated using measured GFR and Cockcroft-Gault CrCl. Using CKD-EPI or MDRD eGFR may give different results and could lead to inappropriate dosing. Most institutions use Cockcroft-Gault or measured GFR for carboplatin calculations.

• What AUC should I target for ovarian cancer?

  First-line ovarian cancer typically targets AUC 5–7.5 (with paclitaxel). Recurrent disease often uses AUC 4–5. The specific AUC depends on the regimen, prior treatments, and patient tolerance. Follow your oncologist's protocol.

• How is carboplatin dose adjusted for renal impairment?

  The Calvert formula inherently adjusts for renal function — a lower GFR produces a lower dose. For severe renal impairment (GFR < 30 mL/min), carboplatin use requires careful risk-benefit analysis and dose reductions may be needed beyond what the formula calculates.